Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Open Targets logo — A partnership using human genetics and genomics data for sys...

Open Targets

A partnership using human genetics and genomics data for systematic drug target identification and prioritisation.

Founded 2014 United Kingdom United Kingdom 21 employees Biotechnology, Health and Wellness

General Information

Company Name Open Targets
Founded Year 2014
Location United Kingdom United Kingdom +1
Employees 21
Industries Biotechnology, Health and Wellness
Social

Get notified when Open Targets moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Open Targets

Open Targets is a pioneering biotechnology startup founded in 2014, dedicated to utilizing human genetics and genomics data for systematic drug target identification and prioritization. Collaborating with industry leaders such as Bristol Myers Squibb, Genentech, GSK, Pfizer, and Sanofi, as well as academic partner EMBL-EBI and Wellcome Sanger Institute, Open Targets has established a large-scale, multi-year public-private partnership. The company's flagship offering, the Open Targets Platform (platform.opentargets.org), provides an easily accessible tool for researchers across various disciplines to identify and prioritize therapeutic targets for new medicines. Furthermore, Open Targets Genetics (genetics.opentargets.org) serves as a portal for investigating Genome Wide Association Study (GWAS) data to aid in the identification of causal genes for prioritizing drug targets. This portal aggregates and merges genetic associations from curated literature and newly-derived loci from UK Biobank and FinnGen, integrating functional genomics data and employing statistical fine-mapping to resolve association signals. In addition to data integration, Open Targets complements its approach with large-scale systematic experimental methods to support target identification, prioritization, and validation, emphasizing its commitment to openly sharing data with the scientific community. Overall, Open Targets demonstrates great potential in leveraging cutting-edge genetics and genomics techniques to revolutionize drug target identification and enhance the development of new therapeutics.

Taxonomy: Genomics, Drug Target Identification, Human Genetics, Public-Private Partnership, Bioinformatics, Therapeutic Targets, Data Integration, Functional Genomics, Biomedical Research, Data Sharing

No funding data available for Open Targets yet.

Get notified when Open Targets raises funding

FAQ About Open Targets

A partnership using human genetics and genomics data for systematic drug target identification and prioritisation.
Open Targets was founded in 2014.
Open Targets is headquartered in United Kingdom.
Open Targets operates in the following industries: Biotechnology, Health and Wellness.
Open Targets has approximately 21 employees.

We're actively collecting intelligence on Open Targets.

Track Open Targets to get notified

Don't just browse. Track.

Signal Tracker monitors Open Targets and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy